Atorvastatin sensitises vascular smooth muscle cells, but not endothelial cells, to TNF-α-induced cell death

Current Pharmaceutical Design

Volumn 18, Issue 38, 2012, Pages 6331-6338

  Giordano, Arturo ^a   Romano, Simona ^b   Nappo, Giovanna ^b   Messina, Stefano ^a   Polimeno, Michele ^a   Corcione, Nicola ^a   Calì, Gaetano ^c   Ferraro, Paolo ^a   Monaco, Mario ^a   Zambrano, Nicola ^b,d   Romano, Maria Fiammetta ^b  

^a Pineta Grande Hospital   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CNR   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Atorvastatin; Cell death; Endothelial cells; TNF ; Vascular smooth muscle cells

Indexed keywords

ATORVASTATIN; ENZASTAURIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOTRANSFERASE; PROTEIN KINASE C BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR RISK; CELL DEATH; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEOINTIMA; PRIORITY JOURNAL; REPRODUCIBILITY; SMOOTH MUSCLE FIBER; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

CELL DEATH; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; HEPTANOIC ACIDS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873952218     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803832245     Document Type: Article

References (48)

1. Ruan XZ, Moorhead JF, Tao JL, et al. Mechanisms of Dysregulation of Low-Density Lipoprotein Receptor Expression in Vascular Smooth Muscle Cells by Inflammatory Cytokines. Arterioscler Thromb Vasc Biol 2006; 26: 1150-5.
2. Fichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001; 104: 3023-25.
3. Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-vvvblockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-25.
4. Lee SJ, Kim WJ, Moon SK. TNF-alpha regulates vascular smooth muscle cell responses in genetic hypertension. Int Immunopharmacol 2009; 9: 837-43.
5. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-6.
6. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66: 1403-8.
7. Davis C, Fischer J, Ley K and Sarembock IJ. The role of inflammation in vascular injury and repair. J Thromb Haemost 2003; 1: 1699-709.
8. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61: 671-82.
9. Pollman MJ, Hall JL, Mann MJ, Zhang LN, Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998; 4: 222-7.
10. Avis HJ, Vissers MN, Stein EA, et al. A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-10.
11. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648-57.
12. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res1992; 33: 1569-82.
13. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
14. Hölschermann H, Schuster D, Parviz B, Haberbosch W, Tillmanns H, Muth H. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 2006; 185: 240-5.
15. Lee JY, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 2007; 7: 241-8.
16. Ahn KS, Sethi G and Aggarwal BB. Simvastatin Potentiates TNF-aa-Induced Apoptosis through the Down-Regulation of NF---BDependent Antiapoptotic Gene Products: Role of IAABBBBKinase and TGF-beta-Activated Kinase-11. J Immunol 2007; 178: 2507-16.
17. Yamamoto M, Acevedo-Duncan M, Chalfant CE, Patel NA, Watson JE, Cooper DR. The roles of protein kinase C beta I and beta II in vascular smooth muscle cell proliferation. Exp Cell Res 1998; 240: 349-58.
18. Andrassy M, Belov D, Harja E, Zou YS, Leitges M, Katus HA, Nawroth PP, Yan SD, Schmidt AM, Yan SF. Central role of PKCbeta in neointimal expansion triggered by acute arterial injury. Circ Res 2005; 96: 476-83.
19. Giordano A, Romano S, Monaco M, et al. Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells. Am J Physiol Heart Circ Physiol 2012; 302: H135-42.
20. Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCoo. Bioorg Med Chem Lett 2003; 13: 1857-9.
21. Giordano A, Avellino R, Ferraro P, Romano S, Corcione N, Romano MF. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. Am J Physiol Heart Circ Physiol 2006; 290: H2459-65.
22. Calì G, Gentile F, Mogavero S, et al. CDH16/Ksp-Cadherin Is Expressed in the Developing Thyroid Gland and Is Strongly Down-Regulated in Thyroid Carcinomas. Endocrinology 2012; 153: 522-34.
23. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci 2004; 117: 5197-208. Review.
24. Byun HS, Park KA, Won M, et al. Phorbol 12-myristate 13-acetate protects against tumor necrosis factor (TNF)-induced necrotic cell death by modulating the recruitment of TNF receptor 1-associated death domain and receptor-interacting protein into the TNF receptor 1 signaling complex: Implication for the regulatory role of protein kinase C. Mol Pharmacol 2006; 70: 1099-108.
25. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36.
26. Buchner K. Protein kinase C in the transduction of signals toward and in the cell nucleus. Eur J Biochem 1995; 228: 211-21.
27. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C hII regulates Akt phosphorylation on Ser-473 in a cell type-and stimulus-specific fashion. J Biol Chem 2004; 279: 47720-5.
28. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7, 281-94.
29. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. 1990; Am J Pathol 137: 503-9.
30. Jovinge S, Hultgardh-Nilsson A, Regnstrom J, Nilsson J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol 1997; 17: 490-7.
31. Clausell N, de Lima VC, Molossi S, et al. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 1995; 73: 534-9.
32. Monaco C, Andreakos E, Kiriakidis S, Feldmann M, Paleolog E. Tcell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004; 3: 35-42.
33. Baud V and Karin M. Signal transduction by tumor necrosis factor and its relatives. TRENDS in Cell Biology 2001; 11: 372-7.
34. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-9.
35. Zhou Z, Lauer MA, Wang K, et al. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 2002; 16: 153-9.
36. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, et al. Influence of anti-TNF-IIIinfliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 2006; 24: 373-9.
37. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-459.
38. Clarke DL, Sutcliffe A, Deacon K, Bradbury D, Corbett L, Knox AJ. PKCbetaII augments NF-kappaB-dependent transcription at the CCL11 promoter via p300/CBP-associated factor recruitment and histone H4 acetylation. J Immunol 2008; 181: 3503-14.
39. Dekker LV, Parker PJ. Protein kinase C: a question of specificity. Trends Biochem Sci 1994; 19: 73-7.
40. Haller H, Ziegler W, Lindschau C and Luft FC. Endothelial Cell Tyrosine Kinase Receptor and G Protein-Coupled Receptor Activation Involves Distinct Protein Kinase C Isoforms. Arterioscler Thromb Vasc Biol 1996; 16: 678-86.
41. Tanaka K, Honda M, Takabatake T. Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 2004; 31: 360-4.
42. Yasunari K, Maeda K, Minami M, Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001; 21: 937-42.
43. Steinberg SF. Structural Basis of Protein Kinase C Isoform. Function Physiol Rev 2008; 88: 1341-78.
44. Nachtigal P, Pospisilova N, Vecerova L, et al. Atorvastatin Increases Endoglin, SMAD2, Phosphorylated SMAD2/3 and eNOS Expression in ApoE/LDLR Double Knockout Mice. J Atheroscler Thromb 2009; 16: 265-74.
45. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-69. Review.
46. van Laake LW, van den Driesche S, Post S, et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 2006; 114: 2288-97.
47. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nature Genet 1996; 13: 189-95.
48. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534-7